F022 Controversies in Cosmetic Dermatology: An International Experience
DESCRIPTION
Cosmetic dermatology often evolves faster than the evidence supporting its treatments. New techniques and products can become widely adopted before their efficacy, safety, and long-term outcomes have been adequately evaluated. In this environment, distinguishing established benefits from plausible mechanisms, personal experience, and persuasive marketing is essential to making informed clinical decisions.
This interactive, debate-style session will examine four common clinical choices, with internationally renowned experts presenting competing arguments grounded in published evidence and clinical experience. Each speaker will make the strongest case for their assigned approach, challenge the opposing position, and address areas where the evidence remains uncertain or conflicting.
The debates will extend beyond whether a treatment works to consider how well it works, for whom, and at what cost or risk. Discussions will explore efficacy, safety, durability, patient selection, and practical considerations, while examining the quality and limitations of the studies supporting each position. Particular attention will be given to whether reported improvements translate into meaningful benefits for patients and whether the findings are applicable to everyday practice.
Audience polling will capture participants’ views and reveal whether the arguments presented change their clinical perspectives. Through contrasting interpretations of the evidence and direct exchanges between speakers, participants will be encouraged to question familiar practices, recognize gaps in current knowledge, and refine their treatment decisions. The aim is to equip clinicians with a more critical and balanced approach to evaluating cosmetic interventions and discussing treatment options with their patients.
LEARNING OBJECTIVES
Develop a stronger understanding of evidence-based practice in the field of cosmetic dermatology.
Design a management plan when addressing commonly practiced cosmetic procedures.
Distinguish the differences between common practices and the scientific basis of individual treatment options.
SCHEDULE
9:00 AM
Access to a dermatologist: Medical
Esther Ellen Freeman, MD, PhD, FAAD
9:12 AM
Access to a dermatologist: Cosmetic
9:24 AM
Q&A
Esther Ellen Freeman, MD, PhD, FAAD
9:30 AM
Melasma: Better results with Chemical Peels
Aseem Sharma, MD, MBA, IFAAD
9:42 AM
Melasma: Better Results with Lasers
Omar Ibrahimi, MD, PhD, FAAD
9:54 AM
Q&A
Omar Ibrahimi, MD, PhD, FAAD, Aseem Sharma, MD, MBA, IFAAD
10:00 AM
Botulinum Toxin: Better Results with Microtox
Doris M. Hexsel, MD, IFAAD
10:12 AM
Botulinum Toxin: Better Results with Traditional Dosing
Rungsima Wanitphakdeedecha, MD, IFAAD
10:24 AM
Q&A
Doris M. Hexsel, MD, IFAAD, Rungsima Wanitphakdeedecha, MD, IFAAD
10:30 AM
Biostimulators: PLLA
Samar Khalil
10:42 AM
Biostimulators: CaHA
Hassan I. Galadari, MD, FAAD
10:54 AM
Q&A
Hassan I. Galadari, MD, FAAD, Samar Khalil
DIRECTOR
Hassan I. Galadari, MD, FAAD
United Arab Emirates University
SPEAKERS
Esther Ellen Freeman, MD, PhD, FAAD
Doris M. Hexsel, MD, IFAAD
Hexsel Dermatologic Clinics - Private Clinics Rio de Janeiro and Porto Alegre, Brazil.
Omar Ibrahimi, MD, PhD, FAAD
Samar Khalil
Aseem Sharma, MD, MBA, IFAAD
Rungsima Wanitphakdeedecha, MD, IFAAD
Department of Dermatology, Faculty of Medicine Siriraj Hosptial, Mahidol University, Bangkok, THAILAND
DISCLOSURES
Esther Ellen Freeman, MD, PhD, FAAD
American Academy of Dermatology – Advisory Board(No Compensation Received); British Journal of Dermatology – Other(Salary); CeraVe – Advisory Board(Honoraria); Harvard University – Speaker(Honoraria); International League of Dermatologic Societies – Investigator(Grants/Research Funding); L'Oreal – Advisory Board(Honoraria); National Institutes of Health – Investigator(Grants/Research Funding); UpToDate, Inc – Other(Honoraria);
Hassan I. Galadari, MD, FAAD
No financial relationships exist with ineligible companies.
Doris M. Hexsel, MD, IFAAD
Baiersdorf Eucerin – Speaker(Fees); Galderma – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Rennova – Speaker(Fees);
Omar Ibrahimi, MD, PhD, FAAD
Accure, Inc – Advisory Board(No Compensation Received); Allergan, Inc – Advisory Board(Honoraria); AVAVA, LLC – Investigator(Grants/Research Funding); Cynosure-Lutronic – Consultant (1099 relationship)(Honoraria); Cytrellis Biosystems, Inc – Advisory Board(Honoraria); Quthero, Inc – Consultant (1099 relationship)(Honoraria); Unilever – Stockholder(Stock);
Samar Khalil
No financial relationships exist with ineligible companies.
Aseem Sharma, MD, MBA, IFAAD
Janssen Pharmaceuticals, Inc – Speaker(Honoraria); Menarini Group – Speaker(Honoraria);
Rungsima Wanitphakdeedecha, MD, IFAAD
No financial relationships exist with ineligible companies.